Acrivon Therapeutics, Inc. Common Stock· ACRV
🇺🇸 US · MicroBroad USNASDAQ
- Price
- $2.10
- Day
- -1.41%
- Mkt Cap
- $89.88M
- 52W Range
- $1.27 – $3.56
- Volume
- 126.4K
- Beta
- 1.93
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Acrivon Therapeutics, Inc. (ACRV) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACRV's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Read full article
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D.
Read full article
Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy
Read full article
Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read full article